We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, ...

More women than ever are being screened for cervical cancer, suggesting a policy change made just a few years ago is having a ...

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...